CLA softgel

威海百合生物技术股份有限公司成立于2005年，先后通过了美国NSF工厂认证、美国FDA注册、英国BRCGS认证、HACCP认证、欧盟水产品注册，加拿大FSRN注册、社会责任Smeta认证等国内外知名管理体系认证或注册。可生产软胶囊、硬胶囊、片剂、粉剂、颗粒剂、口服液、滴剂、瓶饮、软饮等10余种剂型，4000余种营养保健食品，现有保健食品文号六百余个，产品出口欧美等60余个国家和地区，致力于以优质产品持续领跑行业。 威海百合认为，创新产品能够大大留存用户，保持优良品质经受得住消费者以及时间的考验。故而威海百合决定从传统工厂到智能化工厂方向发展，运用产品数字化、生产数字化、设备数字化、管理数据化，实以实现“6个1”数字化管理目标。同时威海百合还建有CNAS实验室认可标准的检测中心，拥有专业的研发团队，同时与中科院、中国海洋大学等多个知名高校合作，不断加大研发投入，根据消费者的需求，对自身的产品进行创新。 如今的威海百合已经拥有从研发、法规、生产、检测、质量管理到采购、仓储、物流，八大部门建立的强大供应链管理，致力打造全球领先的营养食品生产加工基地。 Weihai Baihe Biotechnology Co., Ltd. (hereinafter referred to as "Biohigh"), established in November 2005, is one of the leading national high-tech company specializing in the research, development, production and sales of nutrition and health food. Listed on the main board of the Shanghai Stock Exchange in January 2022, stock code: 603102, it is the first stock listed on the main board of the nutrition and health food industry. Biohigh has a high level of large-scale production capacity in the field of nutrition and health food manufacturing with an international advanced automated production system, which is linked through ERP, MES, WMS, SRM intelligent information systems. Based on that system, the company can conduct in-depth data exchange and interconnection, quickly respond to market demands, and improve delivery rates. Biohigh owns 2 main GMP factories, covering an area of 300 mu (20 hectares) and 20,000 GMP workshops, with over 1000 employees, which can produce more than 10 dosage forms such as soft capsules, hard capsules, tablets, powders, granules, oral liquids, drops, bottle drinks and soft drinks. The daily production capacity of all products has exceeded 3 million bottles (boxes, bags). Biohigh has successively received the multiple quality management system certifications and registration of well-known trademarks, such as ISO quality certifications, NSF, US FDA Registration, EU fishery Registration No., BRCGS, HACCP, FSRN, Smeta, etc. The products are exported to more than 70contries all over the world R&D innovation is the core driving force for Biohigh's rapid development, and the annual R&D investment exceeds 3.6% of sales revenue. It has applied for more than 200 patents successively, and has obtained a number of production qualifications such as health food, general food, supplementary food for pregnant and infants, and sports nutrition. Every year, more than 400 new products are launched, and more than 700 health food approvals are held. Biohigh has always believed that quality is the foundation for the sustainable development of an enterprise. The company has a testing center that meets the requirements of CNAS standards, more than 120 sets of imported testing equipment, and more than 400 testing items. In terms of process control, the company has continuously improved the quality management system and product traceability system, and established 14 quality control points to strictly control the life quality of each product. To be a respected enterprise, to be a product of conscience and quality of life -Biohigh is committed to improving and protecting people’s health.